首次精神病性躁狂发作后心境稳定剂与第二代抗精神病药单药及联合治疗的比较效果:北美、智利和西班牙的靶试验模拟
基于BD-CAUSAL协作组数据模拟靶试验,纳入371例首次精神病性躁狂发作的双相I型障碍患者(465次治疗启动),随访2年。与第二代抗精神病药单药治疗相比,心境稳定剂单药和联合治疗的精神科住院或急诊就诊风险更低,心境稳定剂单药与联合治疗风险相似。
要点
- 首次精神病性躁狂发作后,心境稳定剂单药或联合治疗较第二代抗精神病药单药治疗2年精神科住院或急诊风险更低。
- 心境稳定剂单药与联合治疗之间的2年精神科住院或急诊风险相似。
- 结果支持在早期治疗中优先考虑心境稳定剂,但需随机对照试验确认。
核心结论
- 在首次精神病性躁狂发作的延续和维持治疗中,以心境稳定剂为基础的治疗策略(单药或联合)较第二代抗精神病药单药治疗的复发风险更低。
研究设计与样本
- 比较启动心境稳定剂单药、第二代抗精神病药单药或联合治疗三种策略,随访至多2年,采用池化逻辑回归估计意向治疗和符合方案效应。
主要发现
- 371例 eligible 个体(465次 eligible 治疗启动)中,141例(38%)为女性,230例(62%)为男性,216例(58%)为白人,155例(42%)为非白人,中位年龄22岁(IQR 19-25)。
- 心境稳定剂单药与联合治疗之间风险相似。
临床怎么用
- 对于首次精神病性躁狂发作后的延续和维持治疗,可优先考虑以心境稳定剂为基础的治疗策略(单药或联合),而非第二代抗精神病药单药。
- 临床决策需结合患者个体情况,并注意该证据来自观察性数据模拟的靶试验,需随机对照试验进一步确认。
局限性
- 本研究为靶试验模拟,基于观察性队列数据,存在未测量混杂可能。
- 有 lived experience 的人未参与研究设计、分析或结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The early stage of bipolar I disorder is considered a crucial period for improving long-term outcomes, yet evidence guiding treatment selection after a first manic episode is scarce. Using data from the BD-CAUSAL Collaboration, we aimed to emulate a pragmatic target trial among individuals aged 16 years or older presenting with a first manic episode with psychotic features. METHODS: For the target trial, individuals were eligible if they were aged 16 years or older, treated at a first-episode psychosis clinic with a diagnosis of bipolar I disorder between Jan 1, 2006, and Dec 31, 2021, with a manic episode (with or without mixed features) with psychotic symptoms based on DSM-5 criteria; not currently hospitalised; had no previous use of mood stabilisers or second-generation antipsychotics in the past 3 months; and had no history of severe side-effects. Treatment strategies compared were initiating mood stabiliser monotherapy, second-generation antipsychotic monotherapy, or combination therapy. Individuals are followed up for up to 2 years. We emulated the target trial using the BD-CAUSAL Collaboration database that includes participants from North America, Chile, and Spain, and is a subset of a large consortium of observational cohorts. Information on mood stabilisers and antipsychotic prescription was identified via data linkages with outpatient and hospitalisation databases. We assessed eligibility for each person-visit between Jan, 1, 2006, and Dec, 31, 2021, and assigned individuals to the treatment strategy that was compatible with their data. The main outcome was hospitalisation or an emergency department visit due to any psychiatry reason over 2 years. Intention-to-treat and per-protocol effects were estimated using pooled logistic regression adjusted for baseline and time-varying confounders. People with lived experience were not involved in the study design, analysis, or interpretation of findings. FINDINGS: Among 371 eligible individuals with bipolar I disorder (465 eligible treatment initiations), 141 (38%) were female, 230 (62%) were male, 216 (58%) were White, 155 (42%) were not White, and the median age was 22 years (IQR 19-25). Of 371 patients, 155 (42%) were hospitalised due to psychiatric reasons over a median of 19·8 months (IQR 16·1-24·0). The 2-year hospitalisation or emergency department visit risk was 42·3% (95% CI 32·5 to 61·1) for mood stabiliser monotherapy, 49·5% (42·4 to 60·6) for second-generation antipsychotic monotherapy, and 42·2% (33·3 to 52·5) for combination therapy. Compared with second-generation antipsychotic monotherapy, the risk was lower with mood stabiliser monotherapy (risk difference -7·3% [95% CI -15·8 to -1·4]; risk ratio 0·82 [0·63 to 0·97]) and combination therapy (-7·4% [-16·0 to -2·1]; 0·82 [0·63 to 0·91]). Risks were similar between mood stabiliser monotherapy and combination therapy. INTERPRETATION: Mood stabiliser-based strategies, alone or in combination, had a lower relapse risk than second-generation antipsychotic monotherapy in the continuation and maintenance treatment after a first episode of mania with psychotic symptoms. These findings would support prioritising mood stabilisers in early treatment and highlight the need for randomised trials for confirmation. FUNDING: ASISA and National Institute of Mental Health.
引用
- Szmulewicz AG, Liang YH, Martínez-Alés G, et al. Comparative effectiveness of mood stabiliser monotherapy versus second-generation antipsychotic monotherapy versus combination therapy for continuation and maintenance treatment after a first episode of psychotic mania in North America, Chile, and Spain: a target trial emulation using data from the BD-CAUSAL Collaboration. Lancet Psychiatry. 2026. PMID: 42716056. doi:10.1016/S2215-0366(26)00239-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。